The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma

Abstract

Background:The application of immune checkpoint inhibitors (ICIs) has changed the treatment of advanced hepatocellular carcinoma. Transcatheter arterial chemoembolization (TACE) is a rst-line treatment for intermediate hepatocellular carcinoma. serving as a local inducer of immunogenic cell death, the e cacy and safety of combined use with ICI have not been evaluated. Although there have been prospective studies aimed at evaluating the e cacy and safety of ICI combined with TACE in BCLC stage B HCC patients, there are few reports on the evaluation of BCLC stage C patients with distant metastasis or portal vein cancer thrombus.Method: Data of unresectable hepatocellular carcinoma patients received PD-1 inhibitor and TACE were collected in Xijing Hospital from June 2019 to December 2022. The tumor response was evaluated according to the Solid Tumor Modi ed Response Evaluation Standard (mRECIST), including complete response (CR), partial response (PR), disease stability (SD), disease progression (PD) objective response rate (ORR) ,and disease control rate (DCR).The progression-free survival (PFS) and overall survival (OS) were used to estimate therapy e cacy. The treatment-related adverse events were evaluated based on National Cancer Institute Common Adverse Event Evaluation Criteria (CTCAE) version 5.0.Result:A total of 42 patients with unresectable hepatocellular carcinoma were included in this study, including 34 males (80.5%) and 8 females (19.5%); The average age is 55 years, ranging from (34 -72); The median follow-up time was 12.3 months, with an ORR of 42.9% and a DCR of 90.5% as of the follow-up time; The median PFS is 7.5 months (95% CI: 5.76-9.23), and the median OS has not yet been reached; 6-months PFS was 62.2%. Safety analysis showed that 41 (97.6%) patients experienced treatment-related adverse reactions, mainly including elevated AST and ALT, fever, elevated bilirubin, hypothyroidism, nausea, abdominal pain, and rash. 40 patients had grade 1/2 adverse reactions, and only 1 patient had grade 3 adverse reactions, manifested as intolerable rash, nausea, and vomiting. Treatment was terminated due to symptomatic treatment and discontinuation of medication. In this study, 3patients with unresectable hepatocellular carcinoma were treated with PD-1 inhibitor combined with TACE to achieve good tumor reduction effect, and underwent liver cancer resection surgery.Conclusion: For patients with unresectable hepatocellular carcinoma, whether in BCLC stage B or stage C, effective systemic therapy (PD-1 inhibitor) combined with local therapy (TACE) can achieve a high rate of tumor regression and objective response. Some patients may even pursue surgical treatment opportunities, and the treatment related adverse reactions are controllable, which is expected to provide new options for extending survival of unresectable hepatocellular carcinoma patients.